Legal & General Group Plc Buys Shares of 72,398 Grail, Inc. (NASDAQ:GRAL)

Legal & General Group Plc bought a new position in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 72,398 shares of the company's stock, valued at approximately $1,292,000. Legal & General Group Plc owned 0.22% of Grail as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new stake in shares of Grail during the 4th quarter worth about $26,000. Lindbrook Capital LLC purchased a new position in Grail in the 4th quarter valued at about $28,000. Wellington Shields Capital Management LLC purchased a new position in Grail in the 4th quarter valued at about $33,000. New York State Common Retirement Fund purchased a new position in Grail in the 4th quarter valued at about $59,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in Grail in the 4th quarter valued at about $64,000.

Insider Activity at Grail

In related news, CFO Aaron Freidin sold 1,816 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the sale, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at approximately $10,457,304. This trade represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Ragusa sold 7,625 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.21, for a total transaction of $237,976.25. Following the completion of the transaction, the chief executive officer now owns 828,662 shares in the company, valued at $25,862,541.02. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,550 shares of company stock valued at $360,436.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on GRAL shares. Canaccord Genuity Group began coverage on Grail in a report on Monday, April 21st. They issued a "buy" rating and a $32.00 price target for the company. Morgan Stanley boosted their price objective on Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 18th.

Grail Trading Down 1.0 %

Shares of GRAL traded down $0.36 during mid-day trading on Thursday, reaching $34.15. The company's stock had a trading volume of 355,794 shares, compared to its average volume of 1,398,663. The company's 50 day moving average is $30.48 and its 200 day moving average is $24.73. Grail, Inc. has a 12-month low of $12.33 and a 12-month high of $63.99.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($4.41) by $2.55. The company had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million. As a group, equities research analysts expect that Grail, Inc. will post -15.15 EPS for the current fiscal year.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.